

REMARKS

Claims 9-14, 22, 25-26, and 28-30 are pending. Claims 1-8, 23 and 24 were previously canceled. Claims 15-21 and 27 are canceled herein. Claims 9, 22, 25, 28, 29, and 30 have been amended. The amendments are made to accept the Examiner's suggestions and attend to minor matters of form. Thus, no new matter has been added. Applicant notes that all cancelations and additions are made without prejudice or disclaimer. Applicant expressly reserves the right to file additional claims in further applications, whether such claims have been previously canceled, withdrawn, or are newly presented.

As an initial matter, Applicants wish to thank Examiner Canella for the grant of an interview on May 16, 2008. In the interview, the pending claims were discussed. It was agreed that claims 22 and 25 would be allowable if amended to recited SEQ ID NOs 2, 3, and 8. Claim 28 and 29 were deemed allowable without amendment. Additional claims were possibly allowable, but would need to be reviewed. In accordance, the claims have been amended according to the Examiner's suggestions.

Claims 9-22 and 25-30 are partially rejected under 35 U.S.C. §112, first paragraph, enablement, regarding certain peptides. Claims 15-21 and 27 are rejected under 35 U.S.C. §112, first paragraph, enablement regarding methods of viral treatment. SEQ ID NOs. 2, 3 and 8 show clear antiproliferative activity and were deemed enabled. Without acceding to the rejection regarding the claimed sequences, Applicants have amended claims 9-22 and 25-30 to recite only SEQ ID NOs. 2, 3 and 8 solely in order to expedite prosecution. Claims 15-21 and 27 have been canceled solely in order to expedite prosecution. Applicants expressly reserve the right to file additional applications to pursue the remaining subject matter. As such, the rejection is obviated.

CONCLUSION

For at least the reasons discussed above, Applicant respectfully requests reconsideration of the rejections of the claims. Applicant believes that these claims define over the prior art of record and are in proper form for allowance. If the undersigned can be of assistance to the Examiner regarding any of the above, please contact the undersigned at the number set forth below.

It is not believed that any additional fees are due; however, in the event that an additional fee is required for this response, the Commissioner is hereby authorized to charge such fees to Deposit Account No: 50-0436.

Respectfully submitted,

By: _____

C. Allen Black, Jr.
Reg. No. 53,835

PEPPER HAMILTON LLP
One Mellon Center, 50th Floor
500 Grant Street
Pittsburgh, PA 15219
Phone: (412) 454-5004
Date: July 7, 2008